Video
Author(s):
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
Revisit Every OncLive On Air Episode From May 2024
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma